Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events
Shots:
- Eli Lilly's P-II clinical evaluation of muvalaplin (10mg, 60mg & 240mg) vs PBO, significantly reduced elevated Lp(a) levels, achieving its 1EP at wk.12. Data was highlighted at AHA 2024 and published in the JAMA
- After 12wks., reductions in the Lp(a) levels were up to 85.8% (intact assay) & 70.0% (apo(a) assay). Based on dosing, the reductions were 47.6%, 81.7% & 85.8% with the intact Lp(a) assay as well as 40.4%, 70.0% & 68.9% with the apo(a) assay at 10, 60 & 240mg, respectively
- 2EPs were also met with all the 3 doses, with significant Lp(a) and apoB reductions. At wk.12, Lp(a) levels <125 nmol/L were achieved by 64.2%, 95.9% & 96.7% vs 6% (intact assay), and 38.9%, 81.9% & 77.4% vs 3.6% (apo(a) assay) of patients. ApoB level reductions were 8.9%, 13.1% & 16.1%
Ref: Eli Lilly | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
